Skip to main content
SpringerLink
Log in

Chinese expert consensus statement on clinical diagnosis and treatment of malignant tumor bone metastasis and bone related diseases

  • Published:
The Chinese-German Journal of Clinical Oncology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. El-Khoury GY, Dalinka MK, Alazraki N, et al. Metastatic bone disease. America College of Radiology. ACR Appropriateness Criteria. Radiology, 2000, 215(suppl): 283–293.

    PubMed  Google Scholar 

  2. NCCN Clinical Practice Guidelines in Oncology (Chinese). Breast Cancer. 1st edition. Available: http://www.nccn-asia.org.

  3. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. V.1.2008. Available: http://www.nccn.org.

  4. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med, 2001, 45: 53–64.

    CAS  PubMed  Google Scholar 

  5. Diel IJ, Kaufmann M, Bastert G. Metastatic bone disease fundamental and clinical aspect. Berlin: Springer-Verlag, 1994. 93–108.

    Google Scholar 

  6. Helms CA, Cann CE, Brunelle FO, et al. Detection of bone marrow metastases using quantitative computed tomograph. Radiology, 1981, 40: 745–750.

    Google Scholar 

  7. Steinborn MM, Heuck AF, Tiling R, et al. Whole-body bone marrow MRI in patients with metastic disease to the skeletal system. J Comput Assist Tomogr, 1999, 23: 123–129.

    Article  CAS  PubMed  Google Scholar 

  8. Peterson JJ, Kransdorf MJ, O’Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res, 2003, 415Suppl: S120–128.

    Article  PubMed  Google Scholar 

  9. Cook GJ, Houston S, Rubens R, et al. Detection of bone metastasis in breast cancer by 182FDG PET: differing metabolic activity in osterblastic and osteolytic lesions. J Clin Oncol, 1998, 16: 3375–3379.

    CAS  PubMed  Google Scholar 

  10. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med, 1998, 25: 1244–1247.

    Article  CAS  PubMed  Google Scholar 

  11. Fohr B, Dunstan CR, Seibel MJ, et al. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab, 2003, 88: 5059–5075

    Article  CAS  PubMed  Google Scholar 

  12. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol, 2003, 21: 1404–1411.

    Article  PubMed  Google Scholar 

  13. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol, 2003, 21: 4042–4057.

    Article  CAS  PubMed  Google Scholar 

  14. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ, 2003, 327: 469.

    Article  CAS  PubMed  Google Scholar 

  15. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol, 2002, 20: 3219–3224.

    Article  CAS  PubMed  Google Scholar 

  16. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med, 1998, 339: 357–363.

    Article  CAS  PubMed  Google Scholar 

  17. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc, 2006, 81: 1047–1053.

    Article  CAS  PubMed  Google Scholar 

  18. Zhou JT, Hu BQ, Liu YL, et al. Phase II clinical trail of zoledronic acid in the treatment of pain caused by malignant tumor osseous metastasis. Chin J Clin Oncol Rehabil (Chinese), 2005, 12: 523–526.

    Google Scholar 

  19. Li QF, Xiao SX. Bornin plus chemotherapy and radiotherapy in the treatment of breast cancer bone metastasis. J Pract Diagn Ther (Chinese), 2004, 18: 152–153.

    Google Scholar 

  20. Peng DQ, Wang ZG, Ning C, et al. Clinical trial on ibandronate in patients with bone pain of malignant tumor. Chin Clin Oncol (Chinese), 2005, 10: 423–424.

    Google Scholar 

  21. Bi MH, Qin FZ, Zheng RS, et al. Efficacy and safety of zoledronic acid injection versus pamidronate for the treatment of metastatic bone cancer. Chin J New Drugs (Chinese), 2005, 14: 1209–1211.

    Google Scholar 

  22. Ren J, Di LJ, Feng FY, et al. A Multicenter randomized, double-blind and double dim comparative studies on zoledronic acid and pamidronate disodium: phase II trials from 12 Centers for treating bone metastasis pain. Chin J Clin Oncol (Chinese), 2006, 33: 1169–1172.

    CAS  Google Scholar 

  23. Guarneri V, Donati S, Nicolini M, et al. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist, 2005, 10: 842–848.

    Article  CAS  PubMed  Google Scholar 

  24. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol, 2005, 23: 8580–8587.

    Article  PubMed  Google Scholar 

  25. WHO. Medical need for opioid analgesics. Achieving balance in national opioids control policy: Guidelines for Assessment. Geneva: WHO Publication, 2000. 3–4.

    Google Scholar 

  26. Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol, 2007, 25: 1423–1436.

    Article  PubMed  Google Scholar 

  27. Ben-Josef E, Shamsa F, Youssef E, et al. External beam radiotherapy for painful osseous metastases: pooled data response analysis. Int J Radiat Oncol Biol Phys, 1999, 45: 715–719.

    CAS  PubMed  Google Scholar 

  28. Wu JS, Wong RK, Lloyd NS, et al. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases — an evidencebased practice guideline. BMC Cancer, 2004, 4: 71.

    Article  CAS  PubMed  Google Scholar 

  29. Jeremic B, Shibamoto Y, Igrutinvic I. Single 4 Gy re-irradiation for painful bone metastasis following single fraction radiotherapy. Radiother Oncol, 1999, 52: 123–127.

    Article  CAS  PubMed  Google Scholar 

  30. van der Linden Y, Lok J, Steenland E, et al. Re-irradiation for painful bone metastasis: A further analysis of Dutch Bone Metastasis Study. Int J Radiat Oncol Biol Phys, 2003, 57: S222.

    Google Scholar 

  31. Windsor PM. Predictors of response to strontium-89 (Metastron) in skeletal metastasis from prostate cancer: report of a single centre’s 10-year experience. Clin Oncol (R Coll Radiol), 2001, 13: 219–227.

    CAS  Google Scholar 

  32. Olea E, Riccabona G, Tian J, et al. Efficacy and toxicity of 153Sm EDTMP in the palliative treatment of painful skeleton metastasis: results of an IAEA international multicenter study [abstract]. J Nucl Med, 2001, 51: 146.

    Google Scholar 

  33. Sartor O, Quick D, Reid R, et al. A double blind placebo-controlled study of 153-Samarium-EDTMP for palliation of bone pain in patients with hormone-refractory prostate cancer [abstract]. J Urol, 1997, 157: 321.

    Google Scholar 

  34. Chen S, Xu K, Liu W, et al. Treatment of metastatic bone pain with rhenium-188 hydroxyethylidene diphosphonate. Med Principles Pract, 2001, 10: 98–101.

    Article  CAS  Google Scholar 

  35. Giannakenas C, Kalofonos HP, Apostolopoulos DJ, et al. Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. Am J Clin Oncol, 2000, 23: 83–88.

    Article  CAS  PubMed  Google Scholar 

  36. Silberstein EB, Buscombe JR, McEwan A, et al. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases. Society of Nuclear Medicine Procedure Guidelines Manual. 2003, 3: 147–153.

    Google Scholar 

  37. Galasko CS. Skeletal metastases. Clin Orthop Relat Res, 1986, 210: 18–30.

    PubMed  Google Scholar 

  38. Wedin R, Bauer HC, Wersall P. Failures after operation for skeletal metastatic lesions of long bones. Clin Orthop Relat Res, 1999, 358: 128–139.

    Article  PubMed  Google Scholar 

  39. Bashore CJ, Temple HT. Management of metastatic lesions of the humerus. Orthop Clin North Am, 2000, 31: 597–609.

    Article  CAS  PubMed  Google Scholar 

  40. Harrington KD. Orthopedic surgical management of skletal complications of malignancy. Cancer, 1997, 80(8 Suppl): 1614–1627.

    Article  CAS  PubMed  Google Scholar 

  41. Enneking WF. Musculoskeletal tumor surgery. New York: Churchill Livingstore, 1983.

    Google Scholar 

  42. Wang T, Song ST, Jiang ZF, et al. Clinical trial on ibandronate in patients with tumor-associated hypercalcemia. Chin J Oncol (Chinese), 2004, 26: 739–741.

    CAS  Google Scholar 

  43. Body JJ. Current and future directions in medical therapy: hypercalcemia. Cancer, 2000, 88(12 Suppl): 3054–3058.

    Article  CAS  PubMed  Google Scholar 

  44. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol, 2000, 18: 1570–1593.

    CAS  PubMed  Google Scholar 

  45. Rockville MD. Bone health and osteoporosis: A report of the surgeon general. 2004 Available: http://www.surgeongeneral.gov/library/bonehealth/

  46. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol, 2003, 21: 4042–4057.

    Article  CAS  PubMed  Google Scholar 

  47. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Prostate Cancer v.2.2005. Available: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf.

  48. WHO. Guideline for preclinical evaluation and clinical trials in osteoporosis. Geneva: WHO publication. 1998.

    Google Scholar 

  49. Cheng XG. The International Society of Clinical Densitometry consensus document (2005). Chin J Osteoporos (Chinese), 2006, 12: 205–209.

    Google Scholar 

  50. Chinese Medical Association of Osteoporosis and Bone Mineral Disease Branch. Guidelines for diagnosis and treatment of osteoporosis and bone mineral diseases. Intern J Endocrinol Metab (Chinese), 2006, 26: Appendix 4-3.

    Google Scholar 

  51. Koizumi M, Ogata E. Bone metabolic markers as gauges of metastasis to bone: a review. Ann Nucl Med, 2002, 16: 61–168.

    Article  Google Scholar 

  52. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist, 2006, 11: 1121–1131.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Shiying Yu

  2. Department of Breast Cancer, 307 Hospital of Academy of Military Medical Sciences, Beijing, 100071, China

    Zefei Jiang

  3. State Key Laboratory of Oncology in South China, Department of Nasopharyngeal Carcinoma, Cancer Center of Sun Yat-sen University, Guangzhou, 510060, China

    Li Zhang

  4. The Fourth Clinical Medicine College, Peking University, Beijing, 100035, China

    Xiaohui Niu

  5. Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China

    Lvhua Wang

  6. Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China

    Ning Wu

  7. Department of Urological Surgery, Cancer Hospital and Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China

    Jianhui Ma

Authors
  1. Shiying Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zefei Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaohui Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lvhua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ning Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianhui Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shiying Yu.

Additional information

Prof. Shiying Yu, director of Cancer Center of Tongji Hospital affiliated to Tongji Medical College in Huazhong University of Science & Technology, administrative deputy editor-inchief of Chinese-German Journal of Clinical Oncology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, S., Jiang, Z., Zhang, L. et al. Chinese expert consensus statement on clinical diagnosis and treatment of malignant tumor bone metastasis and bone related diseases. Chin. -Ger. J. Clin. Oncol. 9, 1–12 (2010). https://doi.org/10.1007/s10330-009-0188-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-009-0188-2

Keywords

Search

Navigation